摘要
目的：评价小剂量重组组织型纤溶酶原激活物（ｒｔＰＡ）静脉溶栓治疗国人急性心肌梗死（ＡＭＩ）的疗效及安全性。方法：６６例ＡＭＩ患者随机分为ｒｔＰＡ组３１例及尿激酶（ＵＫ）组３５例，分别应用ｒｔＰＡ及ＵＫ治疗。结果：心肌梗死相关血管再通率ｒｔＰＡ组８０．６％与ＵＫ组４８．６％比较，Ｐ＜０．０５；４周住院病死率ｒｔＰＡ组０与ＵＫ组８．６％比较，Ｐ＜０．０５；而２组间出血发生率无差异。结论：小剂量ｒｔＰＡ治疗ＡＭＩ血管再通率高，出血并发症少，可降低ＡＭＩ早期病死率。
Objective:To evaluate the clinical efficacy and safety of intravenous thrombolytic therapy using low dose recombinant tissue plasminogen activator (rtPA) in Chinese patients with acute myocardial infarction (AMI).Methods:66 cases were divided into rtPA group (31 cases) and urokinase (UK) group (35 cases),which were treated with low dose rtPA and UK,respectively.Results:The clinical reperfusion rates of infarctrelated arteries in rtPA and UK groups were 80 6% and 48 6%,respectively ( P <0 05).The total 4week mortality in rtPA and UK groups were 0 and 8 6% ( P <0 05),respectively,but bleeding rate in 2 groups was not markedly different.Conclusions:The results suggest that low dose rtPA appears to be an effective,reliable and safe thrombolytic agent for AMI.
出处
《中国危重病急救医学》
CSCD
1999年第1期34-35,共2页
Chinese Critical Care Medicine
关键词
尿激酶
溶栓疗法
RT-PA
心肌梗塞
low dose recombinant tissue type plasminogen activator\ \ urokinase\ \ intravenous thrombolytic therapy\ \ acute myocardial infarction
